Mode
Text Size
Log in / Sign up

Preoperative model predicts functional outcomes after glioma resection using clinical and MRI variablesAI predicts brain tumor recovery before surgery begins

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider this preoperative model for risk stratification in glioma resection, but note its moderate and uncertain performance.

This retrospective cohort study included 552 consecutive adults (18 years and older) undergoing first resection of supratentorial contrast-enhancing glioma (WHO grade 2 and above, histopathologically confirmed postoperatively) at a single center. The intervention was a preoperative-only prediction model using clinical variables (age, sex, preoperative KPS, preoperative seizures) and MRI-based tumor characteristics extracted via deep learning. There was no reported comparator.

The primary outcome was functional status at one-year follow-up, classified as mortality (KPS = 0), functional dependence (KPS 10-60), or functional independence (KPS = 70 and above). For mortality, the model's ROC-AUC was 0.77 (95% confidence interval 0.70-0.84). For functional dependence, the ROC-AUC was 0.64 (95% confidence interval 0.52-0.77). For functional independence, the ROC-AUC was 0.71 (95% confidence interval 0.63-0.79). The model provided reliable predictions for 18% of patients, moderate uncertainty for 57%, and identified 25% with genuinely unpredictable outcomes.

Safety and tolerability were not reported. Key limitations include that most existing models incorporate histopathological or postoperative variables unavailable before surgery, and MRI-based predictors did not improve performance as the best-performing model included three predictors: age at diagnosis, contrast-enhancing volume, and preoperative KPS.

The practice relevance is that the model enables individualized risk stratification and may help clinicians identify patients with uncertain prognoses warranting more intensive preoperative counseling or follow-up planning. This evidence is observational and preliminary.

Imagine facing brain surgery without knowing how you will feel a year later. Uncertainty weighs heavy on patients and families during this scary time. Doctors often have to give broad guesses about the future.

Gliomas are aggressive brain tumors that affect thousands of people each year. These growths can change how a person moves, speaks, or thinks. Patients need to know if they will return to work or need help with daily tasks.

Current methods often rely on general statistics that do not fit every person. This leaves many families in the dark about what to expect.

A new tool for brain tumor planning

Usually, doctors rely on general statistics to guess outcomes. This new research changes the game by using artificial intelligence to look at specific scans. The goal is to give a more personal picture of recovery.

The study focused on a specific type of brain tumor called contrast-enhancing glioma. This type often grows quickly and requires surgery to remove as much as possible.

How the computer sees the tumor

Think of the AI like a traffic controller watching every car on the road. It scans the MRI images to spot patterns humans might miss. The computer looks at the shape and size of the tumor.

It also checks the patient's age and how they were doing before the operation. These details help the model build a clearer picture of the future.

Researchers looked at 552 adults who had brain tumor surgery. They used computer models to analyze MRI scans and patient history before the cut. The team wanted to see if they could predict status one year later.

The model predicted who would recover well with good accuracy. Age and the size of the tumor were the most important clues.

Most patients could expect to live independently after one year. However, predicting those who would struggle was much harder for the computer.

But there is a catch.

This does not mean every patient will get a clear answer.

Experts say this helps doctors plan better conversations with families. It allows for more honest discussions about risks before the knife touches skin.

Why some outcomes stay a mystery

The tool only gave confident answers for a small group of people. Many patients still fall into a gray area of uncertainty. The computer could not predict outcomes for everyone with high confidence.

This limitation is important for doctors to understand. It means the tool works best for some cases but not all.

Patients should talk to their doctors about this new technology. It is not a crystal ball but a helpful guide for decision making.

The road ahead for brain surgery

More studies are needed to test this in different hospitals. Approval from health regulators will take time before it is widely used.

Scientists must verify the results in larger groups of people. They also need to ensure the model works across different types of scanners.

Research takes time to move from a lab to a clinic. But this step brings us closer to personalized care for brain tumor patients.

The open-source model allows other researchers to check the work. This transparency helps build trust in the medical community.

Doctors can use these insights to prepare patients for the road ahead. Knowing the risks helps families make informed choices about treatment.

The future of brain surgery may rely more on data than ever before. This shift could lead to better outcomes for many people.

We are still learning how to use these tools safely. But the progress shows promise for those facing difficult diagnoses.

The journey from research to real-world use is long. Yet every step forward helps improve how we care for patients.

This technology offers hope for clearer answers in a complex field. It gives doctors a new way to support their patients.

The focus remains on helping people live better lives after surgery. That is the true goal of this medical research.

Study Details

Study typeCohort
Sample sizen = 552
EvidenceLevel 3
PublishedApr 2026
View Original Abstract ↓
Background and Objectives Preoperative prediction of functional outcomes in contrast-enhancing glioma could support surgical decision-making and patient counseling, yet most existing models incorporate histopathological or postoperative variables unavailable before surgery. Our objectives were to develop a preoperative-only prediction model for one-year functional status and evaluate the added value of MRI-based tumor characteristics beyond clinical predictors. Methods We conducted a retrospective cohort study of consecutive adults (18 years old and older) undergoing first resection of supratentorial contrast-enhancing glioma (WHO grade 2 and above, histopathologically confirmed postoperatively) at a single center, with one-year follow-up. The primary outcome was functional status classified as mortality (Karnofsky Performance Score (KPS) = 0), functional dependence (KPS 10-60), or functional independence (KPS = 70 and above). In addition to clinical variables (age, sex, preoperative KPS, preoperative seizures), a deep learning tool was used to extract structural MRI-based tumor characteristics as predictors. A machine-learning model was developed and conformal prediction was applied to stratify patients by prediction confidence level. Results 552 patients were included (median age: 60 years, range: 18-84; median contrast-enhancing volume: 24 mL, IQR: 10-43; median preoperative KPS: 80, range: 30-100; retrospectively confirmed 88% glioblastoma). Most MRI-based predictors did not improve performance as the best-performing model included three predictors: age at diagnosis, contrast-enhancing volume, preoperative KPS. Bootstrapped areas under the curves were 0.77 (95% confidence interval 0.70-0.84) for mortality, 0.64 (0.52-0.77) for functional dependence, and 0.71 (0.63-0.79) for functional independence. F1 scores per class were 0.65, 0.24, 0.65, respectively. Conformal prediction provided reliable predictions for 18% patients, moderate uncertainty for 57%, and identified 25% with genuinely unpredictable outcomes. Discussion Our preoperative machine-learning model predicted one-year functional status in contrast-enhancing glioma with functional independence being the most reliably classified outcome (ROC-AUC = 0.77, F1 score = 0.65) and functional dependence the most challenging to predict (ROC-AUC = 0.64, F1 score = 0.24). A small set of three preoperative predictors drove model performance, supporting generalizability to broader patient populations. Our open-source model enables individualized risk stratification and may help clinicians identify patients with uncertain prognoses warranting more intensive preoperative counseling or follow-up planning.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.